The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
PPMI Sample Request, 2014Whole Blood RNA Biomarkers of Parkinson’s Disease
Objective/Rationale:
When a Parkinson’s disease patient first experiences motor symptoms, most of the neurons in the part of the brain affected by the disease have already died and therefore the... -
Therapeutic Pipeline Program, 2020Dual-task Augmented Reality Treatment (DART) Protocol for Parkinson’s Disease
Study Rationale:
Approximately 80 percent of people with Parkinson’s disease fall due to problems with posture, walking and balance, known as postural and gait dysfunction (PIGD) one or more times a... -
Research Grant, 2010Longitudinal Follow-Up of Clinical and Neuroimaging Signs and Biomarkers in Symptoms & Side Effects and aSymptoms & Side Effects LRRK2 Mutation Carriers in Comparison to Idiopathic PD and Controls
Objective/Rationale:
Parkinson’s disease (PD) is a common neurodegenerative disease that leads to progressive motor impairment as well as autonomic and cognitive disturbances. The cause of most of... -
MJFF Research Grant, 2010Parkinson's Disease NeuroEPIC: A Study of Genes and the Environment
Objective/Rationale:
We will take advantage of the large European Prospective Investigation in Cancer (EPIC), a unique resource involving almost 500,000 participants from 10 European countries, with... -
Rapid Response Innovation Awards, 2010Ghrelin - a Peripheral, Preclinical Biomarker for Parkinson's Disease
Promising Outcomes of Original Grant:
In our original grant we investigated serum concentrations of the hormone ghrelin in the fasting state and at different time points after a standardized test meal... -
Biomarkers, 2009Development of an alpha6*-Selective Neuronal Nicotinic Receptor (NNR) Imaging Agent as a Parkinson's Disease Biomarker
Objective/Rationale:
The availability of a selective PET radiotracer for the drug target is critical for determining receptor occupancy in humans. NNR subtypes containing the alpha? subunit have been...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.